Hefei Lifeon Pharmaceutical Co., Ltd. (003020.SZ) has announced that it has recently received the formal acceptance notification from the National Medical Products Administration for its clinical trial application concerning the drug registration of a new fixed-dose combination product.

The product in question is a co-crystal formed by the opioid agonist tramadol hydrochloride and the non-steroidal anti-inflammatory drug celecoxib, which is intended to be marketed as a novel pain management therapy.

The proposed indication for this clinical trial is specifically for the treatment of short-term, moderate to severe acute somatic pain in adults. This includes pain arising from post-surgical procedures, such as those following orthopedic, trauma, or dental surgeries, as well as musculoskeletal pain originating from injuries to muscles, ligaments, tendons, and joints.